IMR Press / FBL / Volume 18 / Issue 4 / DOI: 10.2741/4177

Frontiers in Bioscience-Landmark (FBL) is published by IMR Press from Volume 26 Issue 5 (2021). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on as a courtesy and upon agreement with Frontiers in Bioscience.

Open Access Review

Hepatitis B virus X protein in the proliferation of hepatocellular carcinoma cells

Show Less
1 Department of Hepatobiliary Surgery, the First Affiliated Hospital of Dalian Medical University, Dalian, China
Academic Editor:Wei Qin
Front. Biosci. (Landmark Ed) 2013, 18(4), 1256–1265;
Published: 1 June 2013
(This article belongs to the Special Issue Pathogenesis and diagnostic modalities in cancer)

Hepatocellular carcinoma (HCC) is one of the most common and deadly malignant neoplasms worldwide. Chronic hepatitis B virus (HBV) infection is closely associated with the occurrence of HCC. The HBV genome encodes a ubiquitous transactivator, termed the HBV X protein (HBx), that is essential for HBV replication in vivo. HBx is involved in multiple steps of carcinoma development. Even in the preneoplastic stage, HBx acts as a tumor promoter. HBx participates in several mechanisms that have been linked to cell proliferation, including gene transcription, cell cycle regulation, and several signaling pathways. Moreover, HBx mutants, especially those with mutations in the COOH-terminal end, have been implicated in hepatocarcinogenesis. Therefore, therapeutic strategies targeting HBx could be effective at multiple stages of HCC development, even as early as the preneoplastic stage.

Hepatocellular Carcinoma
Hepatitis B virus X protein
Back to top